Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.1 KB
2025-12-01 08:30
Report Publication Announcement
Financial Calendar 2026
English 69.6 KB
2025-12-01 08:30
Report Publication Announcement
Financial calendar for 2026
English 1.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar 2026
Slovene 104.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar za leto 2026
Slovene 1.1 KB
2025-11-24 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.6 KB
2025-11-24 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-11-24 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 119.2 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950

Talk to a Data Expert

Have a question? We'll get back to you promptly.